These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27684354)

  • 21. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of a pharmaceutical care program for elderly diabetic and hypertensive patients in primary health care: a 36-month randomized controlled clinical trial.
    Obreli-Neto PR; Marusic S; Guidoni CM; Baldoni Ade O; Renovato RD; Pilger D; Cuman RK; Pereira LR
    J Manag Care Spec Pharm; 2015 Jan; 21(1):66-75. PubMed ID: 25562774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.
    Aspinall SL; Smith KJ; Good CB; Zhao X; Stone RA; Tonnu-Mihara IQ; Cunningham FE
    Appl Health Econ Health Policy; 2013 Dec; 11(6):653-60. PubMed ID: 24092553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.
    Sullivan PW; Arant TW; Ellis SL; Ulrich H
    Pharmacoeconomics; 2006; 24(10):1021-33. PubMed ID: 17002484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Intensive Blood Pressure Management.
    Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
    JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
    Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
    Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgery for degenerative cervical myelopathy: a patient-centered quality of life and health economic evaluation.
    Witiw CD; Tetreault LA; Smieliauskas F; Kopjar B; Massicotte EM; Fehlings MG
    Spine J; 2017 Jan; 17(1):15-25. PubMed ID: 27793760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial.
    Borenstein JE; Graber G; Saltiel E; Wallace J; Ryu S; Archi J; Deutsch S; Weingarten SR
    Pharmacotherapy; 2003 Feb; 23(2):209-16. PubMed ID: 12587810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term cost-effectiveness of home versus clinic-based management of chronic heart failure: the WHICH? study.
    Maru S; Byrnes JM; Carrington MJ; Stewart S; Scuffham PA
    J Med Econ; 2017 Apr; 20(4):318-327. PubMed ID: 27841726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of pharmacist interventions in patients with heart failure in Thailand.
    Arunmanakul P; Chaiyakunapruk N; Phrommintikul A; Ruengorn C; Permsuwan U
    J Am Pharm Assoc (2003); 2022; 62(1):71-78. PubMed ID: 34756525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
    Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
    Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension.
    Smith SM; Carris NW; Dietrich E; Gums JG; Uribe L; Coffey CS; Gums TH; Carter BL
    J Am Soc Hypertens; 2016 Apr; 10(4):307-17. PubMed ID: 26852290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
    Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM
    Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of pharmacist care for managing hypertension in Canada.
    Marra C; Johnston K; Santschi V; Tsuyuki RT
    Can Pharm J (Ott); 2017; 150(3):184-197. PubMed ID: 28507654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial.
    Henderson C; Knapp M; Fernández JL; Beecham J; Hirani SP; Cartwright M; Rixon L; Beynon M; Rogers A; Bower P; Doll H; Fitzpatrick R; Steventon A; Bardsley M; Hendy J; Newman SP;
    BMJ; 2013 Mar; 346():f1035. PubMed ID: 23520339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G; Burke TA; Carides G
    J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.